SAT0471 TRENDS IN CLINICAL CHARACTERISTICS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY IN RESPONSE TO BIOLOGIC THERAPY IN PSORIATIC ARTHRITIS -ANALYSES FROM THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/
Background: Achievement of minimal disease activity (MDA) may represent an objective target for treatment for patients with psoriatic arthritis (PsA).
1 A patient is considered to have achieved MDA when 5 of the following 7 criteria are met: tender joint count (TJC) ≤1, swollen joint count (SJC) ≤1, affected body surface area (BSA) ≤3%, patient pain VAS ≤15, patient global activity VAS ≤20, HAQ score ≤0.5 and tender entheseal points ≤1. (23%) were classified as responders and 114 patients (77%) were non-responders at the second FU visit. The core components of MDA in these patients are shown in Table 1 . Among responders, there were significant improvements in clinical characteristics and PROs such as mean TJC (3.4 vs 2.1 vs 0.6; P=0.004), SJC (2.5 vs 0.8 vs 0.5; P<0.0001), percentage of affected BSA (5.6% vs 2.4% vs 1.4%; P=0.03), patient pain (34.7 vs 26.1 vs 21.9; P=0.007) and HAQ scores (0.6 vs 0.4 vs 0.3; P=0.04); however, there were no significant changes over time for patient global assessment or enthesitis counts (P>0.05). Non-responders failed to have a significant improvement from baseline to the first and second FU visits in TJC, SJC, enthesitis, pain, patient global assessment and percentage of affected BSA (all P>0.05). Conclusions: Only 23% of patients achieved MDA on their index biologic at the second FU visit and were considered responders. Over time, responders showed significant improvements in TJC and SJC, percentage of affected BSA, patient pain and HAQ scores; these most likely contributed to achievement of MDA response. A treat-to-target approach may be considered given the low number of patients in MDA. 
